FDA approves biosimilar competition for J&J's Remicade drug

The Food and Drug Administration granted marketing approval to Inflectra, a biosimilar product to Horsham-based Janssen Biotech’s multibillion-dollar Remicade drug. Janssen Biotech, which formerly operated as Centocor, is a subsidiary of Johnson & Johnson (NYSE: JNJ). Inflectra, the second biosimilar product approved by the FDA, will be co-marketed by Celletrion, a Korean drug company and Pfizer (NYSE:PFE) The FDA action allows Inflectra to be marketed as a treatment for some, but not all, of…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news